The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Treatment of HCV Infection by Targeting MicroRNA
Open accessAbstract
BACKGROUND: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function. METHODS: In this phase 2a study at seven international sites, we evaluated the safety and efficacy of miravirsen in 36 patients with chronic HCV genotype 1 infection. The patients were randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a 29-day period. They were followed until 18 weeks after randomization. RESULTS: Miravirsen resulted in a dose-dependent reduction in HCV RNA levels that endured beyond the end of active therapy. In the miravirsen groups, the mean maximum reduction in HCV RNA level (log10 IU per milliliter) from baseline was 1.2 (P=0.01) for patients receiving 3 mg per kilogram, 2.9 (P=0.003) for those receiving 5 mg per kilogram, and 3.0 (P=0.002) for those receiving 7 mg per kilogram, as compared with a reduction of 0.4 in the placebo group. During 14 weeks of follow-up after treatment, HCV RNA was not detected in one patient in the 5-mg group and in four patients in the 7-mg group. We observed no dose-limiting adverse events and no escape mutations in the miR-122 binding sites of the HCV genome. CONCLUSIONS: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance. (Funded by Santaris Pharma; ClinicalTrials.gov number, NCT01200420.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
Self-citationvan der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Self-citationTherapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Self-citationMurakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T., & Shimotohno, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209283 · Cited by 1,147
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model
Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E. G., Teruya-Feldstein, J., Bell, G. W., & Weinberg, R. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1618 · Cited by 772
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W., Martin, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014463 · Cited by 750
Self-citationCoulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., & Thorgeirsson, S. S. (2009) · Oncogene · doi:10.1038/onc.2009.211 · Cited by 733
Identification of metastasis-related microRNAs in hepatocellular carcinoma
Budhu, A., Jia, H.-L., Forgues, M., Liu, C.-G., Goldstein, D., Lam, A., Zanetti, K. A., Ye, Q.-H., Qin, L.-X., Croce, C. M., et al. (2008) · Hepatology · doi:10.1002/hep.22160 · Cited by 697
microRNA-122 stimulates translation of hepatitis C virus RNA
Henke, J. I., Goergen, D., Zheng, J., Song, Y., Schüttler, C. G., Fehr, C., Jünemann, C., & Niepmann, M. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.244 · Cited by 679
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
Self-citationTherapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N., & van Rooij, E. (2011) · Circulation · doi:10.1161/circulationaha.111.030932 · Cited by 603
Tsai, W.-C., Hsu, P. W.-C., Lai, T.-C., Chau, G.-Y., Lin, C.-W., Chen, C.-M., Lin, C.-D., Liao, Y.-L., Wang, J.-L., Chau, Y.-P., et al. (2009) · Hepatology · doi:10.1002/hep.22806 · Cited by 583
Liver Transplantation in the United States, 1999-2008
Thuluvath, P. J., Guidinger, M. K., Fung, J. J., Johnson, L. B., Rayhill, S. C., & Pelletier, S. J. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03037.x · Cited by 574
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.004 · Cited by 481
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
Morgan, T. R., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., Lee, W. M., Di Bisceglie, A. M., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 479
MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma†‡
Varnholt, H., Drebber, U., Schulze, F., Wedemeyer, I., Schirmacher, P., Dienes, H., & Odenthal, M. (2008) · Hepatology · doi:10.1002/hep.22158 · Cited by 431
Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex
Shimakami, T., Yamane, D., Jangra, R. K., Kempf, B. J., Spaniel, C., Barton, D. J., & Lemon, S. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112263109 · Cited by 397
Urban, T. J., Thompson, A. J., Bradrick, S. S., Fellay, J., Schuppan, D., Cronin, K. D., Hong, L., McKenzie, A., Patel, K., Shianna, K. V., et al. (2010) · Hepatology · doi:10.1002/hep.23912 · Cited by 361
Self-citationSarasin-Filipowicz, M., Krol, J., Markiewicz, I., Heim, M. H., & Filipowicz, W. (2009) · Nature Medicine · doi:10.1038/nm.1902 · Cited by 304
Machlin, E. S., Sarnow, P., & Sagan, S. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012464108 · Cited by 282
Li, Y.-P., Gottwein, J. M., Scheel, T. K., Jensen, T. B., & Bukh, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016606108 · Cited by 186
Silencing of microRNA‐21 in vivo ameliorates autoimmune splenomegaly in lupus mice
Garchow, B. G., Bartulos Encinas, O., Leung, Y. T., Tsao, P. Y., Eisenberg, R. A., Caricchio, R., Obad, S., Petri, A., Kauppinen, S., & Kiriakidou, M. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100171 · Cited by 174
Self-citationKwoh, T. J. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-21 · Cited by 19
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Metadata
- Authors
- Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., Persson, R., King, B. D., Kauppinen, S., Levin, A. A., & Hodges, M. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-05-02
- Volume
- 368
- Issue
- 18
- Pages
- 1685-1694
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157916750
- Cited by
- 2,204
- References
- 29
- FWCI
- 174.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.